| Title: |
MVA-based vaccine candidates encoding the native or prefusion-stabilized SARS-CoV-2 spike reveal differential immunogenicity in humans |
| Authors: |
Mayer, L.; Weskamm, L.; Fathi, A.; Kono, M.; Heidepriem, J.; Krähling, V.; Mellinghoff, S.; Ly, M.; Friedrich, M.; Hardtke, S.; Borregaard, S.; Hesterkamp, T.; Löffler, F.; Volz, A.; Sutter, G.; Becker, S.; Dahlke, C.; Addo, M. |
| Source: |
npj Vaccines |
| Publication Year: |
2024 |
| Collection: |
Max Planck Society: MPG.PuRe |
| Description: |
In response to the COVID-19 pandemic, multiple vaccines were developed using platforms such as viral vectors and mRNA technology. Here, we report humoral and cellular immunogenicity data from human phase 1 clinical trials investigating two recombinant Modified Vaccinia virus Ankara vaccine candidates, MVA-SARS-2-S and MVA-SARS-2-ST, encoding the native and the prefusion-stabilized SARS-CoV-2 spike protein, respectively. MVA-SARS-2-ST was more immunogenic than MVA-SARS-2-S, but both were less immunogenic compared to licensed mRNA- and ChAd-based vaccines in SARS-CoV-2 naïve individuals. In heterologous vaccination, previous MVA-SARS-2-S vaccination enhanced T cell functionality and MVA-SARS-2-ST boosted the frequency of T cells and S1-specific IgG levels when used as a third vaccination. While the vaccine candidate containing the prefusion-stabilized spike elicited predominantly S1-specific responses, immunity to the candidate with the native spike was skewed towards S2-specific responses. These data demonstrate how the spike antigen conformation, using the same viral vector, directly affects vaccine immunogenicity in humans. |
| Document Type: |
article in journal/newspaper |
| File Description: |
application/pdf |
| Language: |
English |
| Availability: |
http://hdl.handle.net/21.11116/0000-000E-538C-7; http://hdl.handle.net/21.11116/0000-000E-538E-5 |
| Rights: |
info:eu-repo/semantics/openAccess ; http://creativecommons.org/licenses/by/4.0/ |
| Accession Number: |
edsbas.E5CF1BB3 |
| Database: |
BASE |